IN2014MN01919A - - Google Patents
Info
- Publication number
- IN2014MN01919A IN2014MN01919A IN1919MUN2014A IN2014MN01919A IN 2014MN01919 A IN2014MN01919 A IN 2014MN01919A IN 1919MUN2014 A IN1919MUN2014 A IN 1919MUN2014A IN 2014MN01919 A IN2014MN01919 A IN 2014MN01919A
- Authority
- IN
- India
- Prior art keywords
- rosuvastatin
- formulated
- compartment
- salt
- pharmaceutical composition
- Prior art date
Links
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 abstract 2
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229960001199 olmesartan medoxomil Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 abstract 2
- 229960000672 rosuvastatin Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010013710 Drug interaction Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120032903 | 2012-03-30 | ||
| PCT/KR2013/002378 WO2013147462A1 (en) | 2012-03-30 | 2013-03-22 | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01919A true IN2014MN01919A (cs) | 2015-07-10 |
Family
ID=49260650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1919MUN2014 IN2014MN01919A (cs) | 2012-03-30 | 2013-03-22 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20150050333A1 (cs) |
| EP (1) | EP2830618B1 (cs) |
| JP (1) | JP6122098B2 (cs) |
| KR (2) | KR101451081B1 (cs) |
| CN (1) | CN104220068B (cs) |
| AU (1) | AU2013240846B2 (cs) |
| CA (1) | CA2866377C (cs) |
| CL (1) | CL2014002581A1 (cs) |
| CY (1) | CY1117909T1 (cs) |
| DK (1) | DK2830618T3 (cs) |
| ES (1) | ES2587912T3 (cs) |
| HU (1) | HUE030674T2 (cs) |
| IN (1) | IN2014MN01919A (cs) |
| LT (1) | LT2830618T (cs) |
| MX (1) | MX362400B (cs) |
| MY (1) | MY166288A (cs) |
| PH (2) | PH12014501813B1 (cs) |
| PT (1) | PT2830618T (cs) |
| RU (1) | RU2616516C2 (cs) |
| SG (2) | SG10201502582PA (cs) |
| WO (1) | WO2013147462A1 (cs) |
| ZA (1) | ZA201407544B (cs) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12303507B2 (en) | 2019-02-26 | 2025-05-20 | Daewoong Pharmaceutical Co., Ltd. | Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0752842Y2 (ja) | 1989-10-04 | 1995-12-06 | タカヤマ金属工業株式会社 | 樋支持具 |
| KR20170083071A (ko) * | 2014-11-11 | 2017-07-17 | 시오노기 앤드 컴파니, 리미티드 | 광에 대해서 불안정한 약물을 함유하는 다층 정제 |
| CN107205987A (zh) * | 2015-01-09 | 2017-09-26 | 奥托泰利克有限责任公司 | 根据auc进行奥美沙坦给药的方法 |
| CN106727579A (zh) * | 2015-11-19 | 2017-05-31 | 哈尔滨圣吉药业股份有限公司 | 一种厄贝沙坦/瑞舒伐他汀复方制剂及其制备方法 |
| CN106727580A (zh) * | 2015-11-19 | 2017-05-31 | 哈尔滨圣吉药业股份有限公司 | 一种阿利沙坦酯/瑞舒伐他汀复方制剂及其制备方法 |
| CN105395551A (zh) * | 2015-11-19 | 2016-03-16 | 哈尔滨圣吉药业股份有限公司 | 一种奥美沙坦酯/瑞舒伐他汀复方制剂及其制备方法 |
| CN105232556A (zh) * | 2015-11-19 | 2016-01-13 | 哈尔滨圣吉药业股份有限公司 | 一种坎地沙坦酯/瑞舒伐他汀复方制剂及其制备方法 |
| CN105232555A (zh) * | 2015-11-19 | 2016-01-13 | 哈尔滨圣吉药业股份有限公司 | 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法 |
| US9989543B2 (en) | 2016-01-11 | 2018-06-05 | Autotelic, Llc | Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension |
| WO2018009842A1 (en) * | 2016-07-08 | 2018-01-11 | Autotelic Llc | Methods for rosuvastatin dosing by auc |
| MY198062A (en) * | 2017-07-17 | 2023-07-31 | Lilly Co Eli | Pharmaceutical compositions |
| KR101992400B1 (ko) * | 2018-04-30 | 2019-06-24 | 보령제약 주식회사 | 약학적 제제 |
| KR20220026641A (ko) * | 2020-08-25 | 2022-03-07 | 주식회사 대웅제약 | 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물 |
| CN113398086A (zh) * | 2021-05-18 | 2021-09-17 | 海南通用三洋药业有限公司 | 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊 |
| CN113476423A (zh) * | 2021-07-05 | 2021-10-08 | 海南通用三洋药业有限公司 | 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1054019A1 (en) * | 1999-05-18 | 2000-11-22 | Shin-Etsu Chemical Co., Ltd. | Low-substituted hydroxypropyl cellulose |
| JP2002145770A (ja) * | 2000-08-30 | 2002-05-22 | Sankyo Co Ltd | 心不全の予防又は治療のための医薬組成物 |
| CA2656181C (en) * | 2006-06-27 | 2011-09-06 | Daiichi Sankyo Company, Limited | Compressed preparation of compositions comprising olmesartan medoxomil |
| US20110212175A1 (en) * | 2006-10-30 | 2011-09-01 | Hanall Biopharma Co., Ltd. | Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor |
| MX2009004681A (es) * | 2006-10-30 | 2009-08-19 | Hanall Pharmaceutical Co Ltd | Composicion compleja de liberacion controlada que comprende bloqueadores del receptor de angiotensina ii e inhibidores de hmg-coa-reductasa. |
| WO2008068217A2 (en) * | 2006-12-04 | 2008-06-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system |
| TWI482641B (zh) * | 2006-12-07 | 2015-05-01 | Daiichi Sankyo Co Ltd | 含有低取代度羥丙基纖維素之醫藥組成物 |
| TWI488658B (zh) * | 2006-12-26 | 2015-06-21 | Daiichi Sankyo Co Ltd | 溶出性之改善方法 |
| TW200927197A (en) * | 2007-10-29 | 2009-07-01 | Daiichi Sankyo Co Ltd | Film coated preparation |
| US20110009482A1 (en) * | 2007-12-04 | 2011-01-13 | Schering Corporation | Methods of treating copd |
| WO2009154810A2 (en) * | 2008-02-25 | 2009-12-23 | Dr. Reddy's Laboratories Ltd. | Delivery systems for multiple active agents |
| JP5554699B2 (ja) * | 2008-03-13 | 2014-07-23 | 第一三共株式会社 | オルメサルタンメドキソミルを含む製剤の溶出性の改善 |
| KR20090114190A (ko) * | 2008-04-29 | 2009-11-03 | 한올제약주식회사 | 방출성이 제어된 ＨＭＧ―ＣｏＡ 환원 효소 억제제와안지오텐신―Ⅱ―수용체 차단제의 복합 조성물 |
| US10574932B2 (en) * | 2008-07-28 | 2020-02-25 | Fox Digital Enterprises, Inc. | System and method of generating subtitling for media |
| JP5827952B2 (ja) * | 2009-10-09 | 2015-12-02 | ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． | 速効性と持続性を同時に有する薬剤学的組成物 |
| GB201003734D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
| EP2438911A1 (en) * | 2010-10-08 | 2012-04-11 | LEK Pharmaceuticals d.d. | Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil |
| US8399011B1 (en) * | 2012-08-10 | 2013-03-19 | Magnifica Inc. | Oral particle compositions containing a core and an acid-soluble coat |
-
2013
- 2013-03-22 MY MYPI2014002534A patent/MY166288A/en unknown
- 2013-03-22 LT LTEP13769567.2T patent/LT2830618T/lt unknown
- 2013-03-22 CN CN201380018083.0A patent/CN104220068B/zh active Active
- 2013-03-22 EP EP13769567.2A patent/EP2830618B1/en active Active
- 2013-03-22 CA CA2866377A patent/CA2866377C/en active Active
- 2013-03-22 ES ES13769567.2T patent/ES2587912T3/es active Active
- 2013-03-22 MX MX2014011510A patent/MX362400B/es active IP Right Grant
- 2013-03-22 SG SG10201502582PA patent/SG10201502582PA/en unknown
- 2013-03-22 US US14/388,115 patent/US20150050333A1/en not_active Abandoned
- 2013-03-22 RU RU2014143536A patent/RU2616516C2/ru active
- 2013-03-22 DK DK13769567.2T patent/DK2830618T3/en active
- 2013-03-22 SG SG11201405198YA patent/SG11201405198YA/en unknown
- 2013-03-22 WO PCT/KR2013/002378 patent/WO2013147462A1/en active Application Filing
- 2013-03-22 AU AU2013240846A patent/AU2013240846B2/en active Active
- 2013-03-22 HU HUE13769567A patent/HUE030674T2/en unknown
- 2013-03-22 IN IN1919MUN2014 patent/IN2014MN01919A/en unknown
- 2013-03-22 KR KR1020130030734A patent/KR101451081B1/ko active Active
- 2013-03-22 PT PT137695672T patent/PT2830618T/pt unknown
- 2013-03-22 JP JP2015503112A patent/JP6122098B2/ja active Active
-
2014
- 2014-06-19 KR KR1020140074778A patent/KR101931195B1/ko active Active
- 2014-08-11 PH PH12014501813A patent/PH12014501813B1/en unknown
- 2014-09-26 CL CL2014002581A patent/CL2014002581A1/es unknown
- 2014-10-17 ZA ZA2014/07544A patent/ZA201407544B/en unknown
-
2016
- 2016-03-03 PH PH12016500420A patent/PH12016500420A1/en unknown
- 2016-08-11 CY CY20161100799T patent/CY1117909T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12303507B2 (en) | 2019-02-26 | 2025-05-20 | Daewoong Pharmaceutical Co., Ltd. | Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01919A (cs) | ||
| CL2014000511A1 (es) | Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer. | |
| PH12018500284B1 (en) | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer | |
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| EA201100032A1 (ru) | Соединения пиридина | |
| WO2015095227A3 (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
| TW201129382A (en) | Antibody formulation and therapeutic regimens | |
| MX378726B (es) | Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares. | |
| CL2014002386A1 (es) | Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras. | |
| PH12014502366B1 (en) | Injectable formulation | |
| UA113538C2 (xx) | Фторметил-5,6-дигідро-4h-$1,3]оксазини | |
| IN2015DN01164A (cs) | ||
| MX344846B (es) | Combinacion de granulos cargados activos con activos adicionales. | |
| CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
| EA201690679A1 (ru) | Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан | |
| IL232701A (en) | Pirazine compounds that inhibit sick kinase, pharmaceutical preparations that contain them and their use in the preparation of drugs | |
| ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| MX347105B (es) | Composiciones farmaceuticas que comprenden hidromorfona y naloxona. | |
| CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. | |
| MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
| PH12018500378A1 (en) | Novel annelated phenoxyacetamides | |
| NZ702253A (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
| CL2014001959A1 (es) | Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer. | |
| TR201009397A2 (tr) | Rosuvastatin içeren farmasötik bileşimler. |